{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-094911","form_type":"8-K","ticker":"ACOG","cik":"0001655923","company_name":"Alpha Cognition Inc.","filed_at":"2025-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.061503+00:00","generated_at":"2026-05-17T04:56:18.996039+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alpha Cognition prices $35M oversubscribed public offering at $6.25/share","bullets":["Gross proceeds of ~$35M from 5.6M shares (incl. pre-funded warrants) at $6.25 per share.","Offering was oversubscribed; led by premier healthcare-dedicated investor and large existing shareholders.","Expected to close Oct 2, 2025; underwriter has 30-day option to purchase up to 840K additional shares.","Net proceeds to accelerate commercial launch of ZUNVEYL (Benzgalantamine) for Alzheimer's disease.","Company expects total cash position of approximately $70 million following the closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-094911","json":"https://secwatch.observer/filing/0001213900-25-094911.json","markdown":"https://secwatch.observer/filing/0001213900-25-094911.md","text":"https://secwatch.observer/filing/0001213900-25-094911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655923/000121390025094911/0001213900-25-094911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655923/000121390025094911/ea0259660-8k_alpha.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:56:18.996039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}